Akero Therapeutics Long Term Debt

As of the most recent data (September 2025), AKRO shows a long-term debt of $290K. That compares with $36M in the prior-year period — down 99.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AKRO's long-term debt is now $290K (was $36M) — a 99.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Akero Therapeutics is outperforming or lagging.

Tracking AKRO's long-term debt over time shows whether Akero Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $290K That compares with $36M in the prior-year period — down 99.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Akero Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $290K) with ownership activity and broader fundamentals.

Akero Therapeutics's long-term debt is $290K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.